Neuraxis (NRXS) Return on Capital Employed (2023 - 2025)
Neuraxis (NRXS) posted Return on Capital Employed of 237.41% for Q4 2025, down 2.89% sequentially from 230.73% in Q3 2025, and up 114664.0% YoY from N/an in Q4 2024.
Neuraxis (NRXS) Return on Capital Employed (2023 - 2025) Analysis & Trends
Neuraxis has reported Return on Capital Employed for 3 years, with the latest figure at 237.41% in Q4 2025.
- Quarterly Return on Capital Employed rose 114664.0% year-over-year to 237.41% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 237.41% (up 114664.0% YoY) and the FY2025 annual result came in at 280.77%, up 329388.0% from the prior year.
- Return on Capital Employed declined to 237.41% in Q4 2025 per NRXS's latest filing, from 230.73% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 942.67% in Q3 2024 and troughed at 1384.04% in Q4 2024.
- A 3-year average of 14.78% and a median of 40.56% in 2025 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed slumped 204146 bps in 2024, then surged 114664 bps in 2025.
- Over 3 years, Return on Capital Employed stood at 657.42% in 2023, then slumped by 311 bps to 1384.04% in 2024, then surged by 83 bps to 237.41% in 2025.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 237.41%, 230.73%, and 262.97% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Neuraxis | 74.54 Mn | 66.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -237.41% |
| Sep 30, 2025 | -230.73% |
| Jun 30, 2025 | -262.97% |
| Mar 31, 2025 | -425.10% |
| Dec 31, 2024 | -1,384.04% |
| Sep 30, 2024 | 942.67% |
| Jun 30, 2024 | 149.62% |
| Mar 31, 2024 | 245.95% |
| Dec 31, 2023 | 657.42% |
| Sep 30, 2023 | 692.35% |